Proximus NV
XBER:BX7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Proximus NV
XBER:BX7
|
BE |
|
M
|
Mersana Therapeutics Inc
F:0M4
|
US |
|
P
|
PPL Corp
XMUN:PP9
|
US |
|
S
|
Silver Mountain Resources Inc
XTSX:AGMR
|
CA |
|
T
|
Tyson Foods Inc
XMUN:TF7A
|
US |
|
F
|
FB Financial Corp
F:2J2
|
US |
Wall St Price Targets
BX7 Price Targets Summary
Proximus NV
According to Wall Street analysts, the average 1-year price target for BX7 is 8.543 EUR with a low forecast of 6.909 EUR and a high forecast of 11.447 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is BX7's stock price target?
Price Target
8.543
EUR
According to Wall Street analysts, the average 1-year price target for BX7 is 8.543 EUR with a low forecast of 6.909 EUR and a high forecast of 11.447 EUR.
What is the Revenue forecast for Proximus NV?
Projected CAGR
-1%
Over the last 14 years, the compound annual growth rate for Revenue has been 0%. The projected CAGR for the next 5 years is -1%.
What is the Operating Income forecast for Proximus NV?
Projected CAGR
-6%
Over the last 14 years, the compound annual growth rate for Operating Income has been -4%. The projected CAGR for the next 3 years is -6%.
What is the Net Income forecast for Proximus NV?
Projected CAGR
-4%
Over the last 14 years, the compound annual growth rate for Net Income has been -4%. The projected CAGR for the next 3 years is -4%.
